Regorafenib Alone or in Combined With Transcatheter Arterial ChEmoembolization in Treatment of Advanced Hepatocellular Carcinoma After First Line Targeted Therapy

RecruitingOBSERVATIONAL

Enrollment

192

Participants

Timeline

Start Date

December 27, 2022

Primary Completion Date

December 27, 2024

Study Completion Date

December 27, 2025

Conditions

Hepatocellular CarcinomaTranscatheter Arterial ChEmoembolizationRegorafenib

Interventions

PROCEDURE

TACE

Transcatheter Arterial Chemoembolization

DRUG

Regorafenib

Regorafenib alone

Trial Locations (1)

RECRUITING

FirstSunYetSen, Guangzhou

All Listed Sponsors

lead

WenBo Guo

OTHER